Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akcea Therapeutics Inc (AKCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,955,273
  • Shares Outstanding, K 85,720
  • Annual Sales, $ 55,210 K
  • Annual Income, $ -109,750 K
  • 36-Month Beta 0.11
  • Price/Sales 35.42
  • Price/Cash Flow N/A
  • Price/Book 6.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.74
  • Number of Estimates 2
  • High Estimate -0.56
  • Low Estimate -0.92
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -311.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.13 +6.42%
on 10/19/18
37.73 -37.58%
on 09/25/18
-3.50 (-12.94%)
since 09/19/18
3-Month
22.13 +6.42%
on 10/19/18
40.75 -42.21%
on 08/07/18
-6.70 (-22.15%)
since 07/19/18
52-Week
15.20 +54.93%
on 11/07/17
40.75 -42.21%
on 08/07/18
+4.34 (+22.59%)
since 10/19/17

Most Recent Stories

More News
Noteworthy Tuesday Option Activity: AKCA, SEAS, WYNN

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Akcea Therapeutics Inc , where a total volume of 1,893 contracts has been traded thus...

AKCA : 23.55 (+3.24%)
Akcea Announces Changes to Board of Directors

Dr. Damien McDevitt replaces Dr. Stanley Crooke on Akcea Board of Directors

AKCA : 23.55 (+3.24%)
IONS : 45.19 (-2.50%)
Akcea Announces Its Access and Distribution Strategy for TEGSEDI(TM) (inotersen)

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.(NASDAQ: IONS), announced today that they are working together with Accredo specialty pharmacy, a subsidiary of Express...

ESRX : 95.30 (-0.88%)
AKCA : 23.55 (+3.24%)
IONS : 45.19 (-2.50%)
Akcea and Ionis Announce Approval of TEGSEDI(TM) (inotersen injection) in Canada

First and only treatment of its kind for Canadians with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy - a rare and inherited disease

AKCA : 23.55 (+3.24%)
IONS : 45.19 (-2.50%)
Are Options Traders Betting on a Big Move in Akcea (AKCA) Stock?

Investors need to pay close attention to Akcea (AKCA) stock based on the movements in the options market lately.

AKCA : 23.55 (+3.24%)
Today's Research Reports on Trending Tickers: Akcea Therapeutics and Alexion Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / September 25, 2018 / U.S. markets closed lower Monday as trade tensions heated up. The Trump administration imposed a tariff of 10 percent on over $200 billion, which could...

AKCA : 23.55 (+3.24%)
Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx

Study demonstrates significant Lp(a) reduction, favorable safety and tolerability profile

AKCA : 23.55 (+3.24%)
IONS : 45.19 (-2.50%)
Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA

Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.

AKCA : 23.55 (+3.24%)
KALA : 9.23 (-3.25%)
IONS : 45.19 (-2.50%)
GILD : 73.27 (-1.21%)
AMGN : 201.80 (-0.45%)
Akcea Therapeutics to Present at the Wells Fargo Healthcare Conference

Akcea Therapeutics, Inc.(NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that management will present a company overview at the Wells Fargo Healthcare Conference at 4:10 p.m....

WFC : 52.89 (-0.40%)
AKCA : 23.55 (+3.24%)
IONS : 45.19 (-2.50%)
DSW and Tiffany rise while Best Buy and Hain stumble

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:

TIF : 107.01 (-2.38%)
TOL : 30.02 (-4.09%)
CPB : 37.93 (+3.44%)
AKCA : 23.55 (+3.24%)
BRKS : 30.70 (-4.39%)
DSW : 25.16 (-4.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade AKCA with:

Business Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx...

See More

Key Turning Points

2nd Resistance Point 26.10
1st Resistance Point 24.82
Last Price 23.55
1st Support Level 22.20
2nd Support Level 20.86

See More

52-Week High 40.75
Fibonacci 61.8% 30.99
Fibonacci 50% 27.98
Fibonacci 38.2% 24.96
Last Price 23.55
52-Week Low 15.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar